{"nctId":"NCT01725529","briefTitle":"An Efficacy, Pharmacokinetics, Safety and Tolerability Study of TMC435 as Part of a Treatment Regimen for Hepatitis C-Infected Patients","startDateStruct":{"date":"2012-11"},"conditions":["Hepatitis C, Chronic"],"count":457,"armGroups":[{"label":"TMC435 150 mg","type":"EXPERIMENTAL","interventionNames":["Drug: TMC435","Drug: Peginterferon-alpha (PegIFNα-2a)","Drug: Ribavirin (RBV)"]},{"label":"TMC435 100 mg","type":"EXPERIMENTAL","interventionNames":["Drug: TMC435","Drug: Peginterferon-alpha (PegIFNα-2a)","Drug: Ribavirin (RBV)"]},{"label":"Control","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Peginterferon-alpha (PegIFNα-2a)","Drug: Ribavirin (RBV)","Drug: Placebo"]}],"interventions":[{"name":"TMC435","otherNames":[]},{"name":"Peginterferon-alpha (PegIFNα-2a)","otherNames":[]},{"name":"Ribavirin (RBV)","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* A liver biopsy within 3 years prior to the screening visit (or between screening and day of randomization) with histology consistent with chronic Hepatitis C virus (HCV) infection\n* Presence of contraindications for a liver biopsy in patients who are otherwise deemed eligible for participation does not exclude the patient from participation\n* Genotype 1 HCV infection (confirmed at screening)\n* Plasma HCV RNA of \\> 10,000 IU/mL at screening\n\nExclusion Criteria:\n\n* Prior treatment with any approved or investigational drug for the treatment of hepatitis C\n* Co-infection with hepatitis B virus or human immunodeficiency virus (HIV)","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"70 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Sustained Virologic Response 12 Weeks After End of Study Drug Treatment (SVR12)","description":"Participants considered to have achieved SVR12 if both conditions are met: 1). the hepatitis C virus ribonucleic acid (HCV RNA) is less than (\\<) lower limit of quantification (LLOQ; 25 international unit per milliliter \\[IU/mL\\]) undetectable at end of treatment and, 2). the HCV RNA is \\< LLOQ detectable or undetectable at 12 weeks after the planned end of study drug treatment.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"75.7","spread":null},{"groupId":"OG001","value":"88.9","spread":null},{"groupId":"OG002","value":"90.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Sustained Virologic Response 24 Weeks After End of Study Drug Treatment (SVR24)","description":"Participants considered to have achieved SVR24 if both conditions are met: 1). the hepatitis C virus ribonucleic acid (HCV RNA) is less than (\\<) lower limit of quantification (LLOQ;25 IU/mL) undetectable at end of treatment and, 2). the HCV RNA is \\< LLOQ detectable or undetectable at 24 weeks after the planned end of study drug treatment.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"75.0","spread":null},{"groupId":"OG001","value":"88.9","spread":null},{"groupId":"OG002","value":"90.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Sustained Virologic Response at Week 72 (SVRW72)","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"75.0","spread":null},{"groupId":"OG001","value":"87.6","spread":null},{"groupId":"OG002","value":"90.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With On-treatment Failure","description":"A participant with on-treatment failure refers to a participant with confirmed detectable HCV RNA at the end of treatment.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.5","spread":null},{"groupId":"OG001","value":"3.3","spread":null},{"groupId":"OG002","value":"3.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Viral Breakthrough","description":"The number of patients who experience viral breakthrough will be determined by measuring Hepatitis C virus (HCV) ribonucleic acid (RNA) levels in plasma. Viral breakthrough was defined as a confirmed increase of \\>1 log10 IU/mL in HCV RNA level from the lowest level reached, or a confirmed HCV RNA level of \\>100 IU/mL in subjects whose HCV RNA levels had previously been below the limit of quantification (\\<25 IU/mL detectable) or undetectable (\\<25 IU/mL undetectable) while on study treatment.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","spread":null},{"groupId":"OG001","value":"2.6","spread":null},{"groupId":"OG002","value":"2.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Viral Relapse","description":"Viral relapse was defined as undetectable HCV RNA at the actual end of treatment and last HCV RNA measurement during follow-up ≥25 IU/mL.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.5","spread":null},{"groupId":"OG001","value":"1.4","spread":null},{"groupId":"OG002","value":"2.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With On-treatment Normalization of Alanine Aminotransferase Level","description":"Percentage of participants with on-treatment normalization of alanine aminotransferase level were assessed.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"85.7","spread":null},{"groupId":"OG001","value":"86.1","spread":null},{"groupId":"OG002","value":"89.9","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":9,"n":152},"commonTop":["Neutrophil count decreased","White blood cell count decreased","Platelet count decreased","Haemoglobin decreased","Anaemia"]}}}